S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in

CytomX Therapeutics Stock Forecast, Price & News

-0.11 (-1.30 %)
(As of 03/2/2021 12:00 AM ET)
Today's Range
Now: $8.34
50-Day Range
MA: $7.93
52-Week Range
Now: $8.34
Volume604,800 shs
Average Volume1.07 million shs
Market Capitalization$385.51 million
P/E RatioN/A
Dividend YieldN/A
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CytomX Therapeutics logo


A Preview Of CytomX Therapeutics's Earnings
February 23, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CTMX
Year FoundedN/A



Sales & Book Value

Annual Sales$57.49 million
Book Value$1.12 per share


Net Income$-102,240,000.00


Market Cap$385.51 million
Next Earnings Date5/6/2021 (Estimated)


Overall MarketRank

1.55 out of 5 stars

Medical Sector

388th out of 1,968 stocks

Pharmaceutical Preparations Industry

199th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-0.11 (-1.30 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

Is CytomX Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CytomX Therapeutics stock.
View analyst ratings for CytomX Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CytomX Therapeutics?

Wall Street analysts have given CytomX Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CytomX Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 3,640,000 shares, an increase of 20.9% from the January 14th total of 3,010,000 shares. Based on an average trading volume of 783,800 shares, the days-to-cover ratio is currently 4.6 days.
View CytomX Therapeutics' Short Interest

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for CytomX Therapeutics

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its earnings results on Tuesday, February, 23rd. The biotechnology company reported ($0.32) EPS for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.18. CytomX Therapeutics had a negative net margin of 58.13% and a negative trailing twelve-month return on equity of 94.20%.
View CytomX Therapeutics' earnings history

How has CytomX Therapeutics' stock price been impacted by Coronavirus?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTMX stock has increased by 42.1% and is now trading at $8.34.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CTMX?

7 Wall Street analysts have issued 12-month target prices for CytomX Therapeutics' stock. Their forecasts range from $8.50 to $16.00. On average, they anticipate CytomX Therapeutics' share price to reach $11.75 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts' price targets for CytomX Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 54, Pay $907.75k)
  • Mr. Frederick W. Gluck, Co-Founder & Independent Director (Age 86, Pay $49.38k)
  • Mr. Lloyd A. Rowland Jr., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 64, Pay $574.06k)
  • Dr. Amy C. Peterson M.D., Exec. VP & Chief Devel. Officer (Age 54, Pay $2.17M)
  • Mr. Carlos Campoy, Sr. VP & CFO (Age 56)
  • Dr. Chau Cheng M.B.A., Ph.D., VP of Investor Relations & Corp. Communications
  • Dr. Sridhar Viswanathan Ph.D., Sr. VP of Process Sciences & Manufacturing Operations
  • Ms. Danielle Olander, Sr. VP, Talent & Systems Devel.
  • Ms. Alison Joly, Sr. VP of Program & Alliance Management
  • Ms. Leslie Robbins, Sr. VP of Intellectual Property

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.23%), Victory Capital Management Inc. (5.01%), Renaissance Technologies LLC (4.47%), Nuveen Asset Management LLC (1.32%), Dimensional Fund Advisors LP (1.20%) and Northern Trust Corp (1.13%). Company insiders that own CytomX Therapeutics stock include Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends for CytomX Therapeutics

Which major investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Renaissance Technologies LLC, Panagora Asset Management Inc., Victory Capital Management Inc., Trexquant Investment LP, Congress Park Capital LLC, and Tudor Investment Corp Et Al.
View insider buying and selling activity for CytomX Therapeutics
or view top insider-selling stocks.

Which major investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Barclays PLC, Assenagon Asset Management S.A., Squarepoint Ops LLC, Charles Schwab Investment Management Inc., Virginia Retirement Systems ET AL, Taddei Ludwig & Associates Inc., and XTX Markets LLC.
View insider buying and selling activity for CytomX Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $8.34.

How much money does CytomX Therapeutics make?

CytomX Therapeutics has a market capitalization of $385.51 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

CytomX Therapeutics employs 158 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

Where are CytomX Therapeutics' headquarters?

CytomX Therapeutics is headquartered at 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]

This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.